Hoping for the best, but... A little while ago, they wanted to do a 12-1 RS, and shareholders didn't approve. Now they want a 100-1.
If the additional news does not include some source of revenue, then the 100-1 RS will be at the expense of us shareholders, which will dilute our investments into oblivion.
Something that really bothers me is that Stero has 3 individuals that are currently (in some way) related to Kalytera; they are Dr. Sari Prutchi Sagiv, Dr. Moshe Yeshurun and David Bassa.
Bassa (current CEO of Stero) was the CEO of Talent Biotech (which Kaly acquired in 2017), and both Dr. Sagiv (also formerly from Talent Bio) and Dr. Yeshurun currently work for/with Kaly and Stero.
It seems like the same people are always involved in these transactions - i.e. in 2-3 years, will there be another company that Kaly will want to buy (again) from Bassa (with Sagiv/Yeshurun)? Are shareholders (again) going to pay for it? Wash/rinse/repeat every few years?
If Kaly really did receive "multiple unsolicitated offers", was the best offer really the one involving the same people they've dealt with in the past? Us shareholders should think about that...
I have a good chunk invested in Kaly and am hoping for the best, but man...something smells and it just can't be ignored.